Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure

European Journal of Pharmacology

Volumn 622, Issue 1-3, 2009, Pages 71-77

  Someya, Yuka ^a   Nakano, Ryosuke ^a   Tahara, Atsuo ^a   Takasu, Toshiyuki ^a   Takeuchi, Asako ^a   Nagase, Itsuro ^a   Matsuyama Yokono, Akiko ^a   Hayakawa, Masahiro ^a   Sasamata, Masao ^a   Miyata, Keiji ^a   Uchiyama, Yasuo ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ASP8497; Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1; Secondary failure; Sulfonylurea

Indexed keywords

4 FLUORO 1 [[[4 METHYL 1 (METHYLSULFONYL)PIPERIDIN 4 YL]AMINO]ACETYL]PYRROLIDINE 2 CARBONITRILE MONOFUMARATE; ASP 8497; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NICOTINAMIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HYPOGLYCEMIA; INHIBITION KINETICS; INSULIN BLOOD LEVEL; INSULIN RELEASE; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; ZUCKER DIABETIC FATTY RAT;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GLUCOSE TOLERANCE TEST; INSULIN-SECRETING CELLS; MALE; MICE; PIPERIDINES; PYRROLIDINES; RATS; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

EID: 70349873519     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.024     Document Type: Article

References (27)

1. 2+ regulation prevail over changes in insulin content. Br. J. Pharmacol. 127 (1999) 1883-1891
2. Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu. Rev. Med. 57 (2006) 265-281
3. Fineman M.S., Shen L.Z., Taylor K., Kim D.D., and Baron A.D. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab. Res. Rev. 20 (2004) 411-417
4. Gribble F.M., and Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 46 (2003) 875-891
5. Gutniak M., Orskov C., Holst J.J., Ahrén B., and Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326 (1992) 1316-1322
6. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P., and Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 9 (2007) 733-745
7. Kaiser N., Leibowitz G., and Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J. Pediatr. Endocrinol. Metab. 16 (2003) 5-22
8. Kawaki J., Nagashima K., Tanaka J., Miki T., Miyazaki M., Gono T., Mitsuhashi N., Nakajima N., Iwanaga T., Yano H., and Seino S. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes 48 (1999) 2001-2006
9. Lohse M.J. Molecular mechanisms of receptor desensitization. Biochim. Biophys. Acta 1179 (1993) 171-188
10. Masiello P., Broca C., Gross R., Roye M., Manteghetti M., Hillaire-Buys D., Novelli M., and Ribes G. Experimental NIDDM: development of a new model in adult rats administered streptozotocine and nicotinamide. Diabetes 47 (1998) 224-229
11. 1c level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice. Naunyn Schmiedebergs Arch. Pharmacol. 379 (2008) 191-199
12. Matsuyama-Yokono A., Tahara A., Nakano R., Someya Y., Nagase I., Hayakawa M., and Shibasaki M. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem. Pharmacol. 76 (2008) 98-107
13. Matsuyama-Yokono A., Tahara A., Nakano R., Someya Y., Shiraki K., Hayakawa M., and Shibasaki M. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism 58 3 (2009) 379-386
14. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., Turner R.C., and UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet. Med. 15 (1998) 297-303
15. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214 (1993) 829-835
16. Nathan D.M., Schreiber E., Fogel H., Mojsov S., and Habener J.F. Insulinotropic action of glucagon-like peptide 1 (7-37) in diabetic and non-diabetic subjects. Diabetes Care 15 (1992) 270-276
17. Penfornis A., Borot S., and Raccah D. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab. 34 (2008) S78-S90
18. Poitout V., and Robertson R.P. Minireview: secondary beta-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 143 (2002) 339-342
19. Remedi M.S., and Nichols C.G. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med. 28 (2008) 1473-1485
20. Rosenstock J., and Fitchet M. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. Int. J. Clin. Pract., Suppl. 159 (2008) 15-23
21. Someya Y., Tahara A., Nakano R., Matsuyama-Yokono A., Nagase I., Fukunaga Y., Takasu T., Hayakawa M., and Shibasaki M. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 377 (2008) 209-217
22. Stahl M., and Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet. Med. 16 (1999) 586-590
23. Tahara A., Matsuyama-Yokono A., Nakano R., Someya Y., and Shibasaki M. Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice. Horm. Metab. Res. 40 (2008) 880-886
24. Tahara A., Matsuyama-Yokono A., Nakano R., Someya Y., Hayakawa M., and Shibasaki M. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice. Eur. J. Pharmacol. 605 (2009) 170-176
25. Turner R.C., Cull C.A., Frighi V., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
26. Vilsbøll T., Krarup T., Madsbad S., and Holst J.J. No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetes Care 18 (2001) 144-149
27. Yamazaki K., Yasuda N., Inoue T., Yamamoto E., Sugaya Y., Nagakura T., Shinoda M., Clark R., Saeki T., and Tanaka I. Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats. J. Pharmacol. Exp. Ther. 320 (2007) 738-746